P

Plus Therapeutics
D

PSTV

0.30230
USD
-0.01
(-3.73%)
مغلق
حجم التداول
7,164
الربح لكل سهم
-0
العائد الربحي
-
P/E
-0
حجم السوق
9,890,365
أصول ذات صلة
AAPL
AAPL
1.945
(0.99%)
198.400 USD
AMZN
AMZN
4.020
(1.90%)
216.160 USD
CMCSA
CMCSA
0.080
(0.23%)
35.100 USD
DIS
DIS
1.550
(1.31%)
119.500 USD
GOOGL
GOOGL
2.075
(1.19%)
176.770 USD
NFLX
NFLX
12.54
(1.03%)
1,225.11 USD
ROKU
ROKU
7.810
(10.50%)
82.210 USD
T
T
-0.200
(-0.71%)
27.970 USD
المزيد
الأخبار المقالات

العنوان: Plus Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).